Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Most of the contraindications to the administration of intravenous (IV) recombinant tissue
plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These …

Importance Clinical evidence of the potential treatment benefit of mechanical thrombectomy
for posterior circulation distal, medium vessel occlusion (DMVO) is sparse. Objective To …

Background and Purpose—The authors present an overview of the current evidence and
management recommendations for evaluation and treatment of adults with acute ischemic …

Objective: To determine patient and hospital characteristics associated with not providing IV
tissue plasminogen activator (tPA) to eligible patients with acute ischemic stroke (AIS) in …

Background—Substantial efforts over the past decade have increased rates of intravenous
tissue plasminogen activator (tPA) use in the United States. We sought to determine …

Objective: The NIH Stroke Scale (NIHSS) may not appropriately assess the spectrum of
posterior circulation (PC)–related neurologic deficits. We determined the cutoff baseline …

Background and Purpose—Mild or rapidly improving stroke is a frequently cited reason for
not giving intravenous recombinant tissue-type plasminogen activator (rtPA), but some of …

Patients with mild stroke are assumed to achieve full recovery with little or no intervention.
However, recent studies suggest that such patients may experience persistent disability and …

Importance Mild strokes have been poorly represented in thrombolytic trials and only a few
series have reported outcomes after treatment with intravenous (IV) recombinant tissue …